Divalproex sodium increases plasma GABA levels in healthy volunteers

International Clinical Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 221-225

  Shiah, I Shin ^a   Yatham, L N ^b   Baker, G B ^c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Divalproex sodium; GABA; Plasma; Valproic acid

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PHTHALALDEHYDE; VALPROATE SEMISODIUM;

AFFECTIVE NEUROSIS; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DROWSINESS; FATIGUE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH PAIN;

EID: 0033930142     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015040-00005     Document Type: Article

References (41)

1. Baker GB, Paslawski T, Rauw G, McKennna KF (1998) An assay for GABA in plasma and its application to phenelzine-treated patients, Proceedings of the 41st Annual Meeting of the Canadian Federation of Biological Sciences. Edmonton, Canada.
2. Berrettini W, Nurnberger JI, Hare TA, Simmons-Alling S, Gershon ES, Post RM (1983) Reduced plasma and CSF γ-aminobutyric acid in affective illness: effect of lithium carbonate. Biol Psychiatry 18:185-194.
3. Berrettini WH, Nurnberger JI, Hare TA, Simmons-Alling S, Gershon ES (1986) CSF GABA in euthymic manicdepressive patients and controls. Biol Psychiatry 21:844-846.
4. Ekwuru MO, Cunningham JR (1990) Phaclofen increases GABA release from valproate treated rats. Br J Pharmacol 99 (Suppl.):251P.
5. Gent JP, Phillips NI (1980) Sodium di-n-propylacetate (valproate) potentiates responses to GABA and muscimol on single central neurons. Brain Res 197:275-278.
6. Godin Y, Heiner L, Mark JPM (1969) Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J Neurochem 16:869-873.
7. Gram L, Larsson OM, Johnsen AH, Schousboe A (1988) Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogeneous and exogenous GABA from cultured neurons. Epilepsy Res 2:87-95.
8. Iadarola MJ, Raines A, Gale K (1979) Differential effects of n-dipropylacetate and aminooxyacetic acid on γ-aminobutyric acid levels in discrete areas of rat brain. J Neurochem 33:1119-1123.
9. Kaiya H, Namba M, Yoshida H, Nakamura S (1982) Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatr Res 6:335-343.
10. Kusumakar V, Yatham LN, Haslam DRS, Parikh SV, Matte R, Silverstone PH, et al. (1997) Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry 42 (Suppl. 2):79S-86S.
11. Larsson OM, Gram L, Schousboe I, Schousboe A (1986) Differential effects of gamma-vinyl GABA and val-proate on GABA-transaminase from cultured neurons and astrocytes. Neuropharmacology 25:617-625.
12. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M (1980) Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 137: 240-244.
13. Loscher W (1979) GABA in plasma and cerebrospinal fluid of different species. Effects of gamma-acetylenic-GABA, gamma-vinyl-GABA and sodium valproate. J Neurochem 32:1587-1591.
14. Loscher W (1980) Effects of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. J Neurochem 34:1603-1608.
15. Loscher W (1981) Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 30:1364-1366.
16. Loscher W (1982) GABA in plasma, CSF, and brain of dogs during acute and chronic treatment with γ-acetylenic GABA and valproic acid. In: Problems in GABA Research. From Brain to Bacteria (Okada Y, Roberts E, eds.), Amsterdam: Exerpta Medica.
17. Loscher W (1989) Valproate enhances GABA turnover in the substantia nigra. Brain Res 501:198-203.
18. Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progr Neurobiol 58:31-59.
19. Loscher M, Schmidt D (1980) Increase of human plasma GABA by sodium valproate. Epilepsia 21:611-615.
20. Loscher W, Schmidt D (1981) Plasma GABA levels in neurological patients under treatment with valproic acid. Life Sci 28:2383-2388.
21. Loscher W, Siemes H (1985) Cerebrospinal fluid γ-aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment. Epilepsia 26:314-319.
22. Loscher W, Vetter M (1985) In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Biochem Pharmacol 34:1747-1756.
23. Maitre M, Ciesielski L, Cash C, Mandel P (1978) Comparison of the structural characteristics of the 4-aminobutyrate: 2-oxoglutarate transaminases from rat and human brain, and of their affinities for certain inhibitors. Biochem Biophys Acta 552:385-399.
24. Mattson RH, Petroff O, Rothman D, Behar K (1994) Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 53 (Suppl. 5):S29-S32.
25. 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain. Epilepsia 36:457-464.
26. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH (1996) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39:95-99.
27. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ (1993a) Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 9:125-132.
28. Petty F, Kramer GL, Hendrickse W (1993b) GABA and depression. In: Biology of Depressive Disorders, Part A: A System Perspectire (Mann JJ, Kupfer DJ, eds.), New York: Plenum Press, pp. 79-108.
29. Petty F, Rush AJ, Davis JM, Calabrese JR, Kimmel SE, Kramer GL, et al. (1996) Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 39:278-284.
30. Phillips NI, Fowler LJ (1982) The effects of sodium valproate on γ-aminobutyrate metabolism and behavior in naïve and ethanolamine-O-sulphate pre-treated rats and mice. Biochem Pharmacol 31:2257-2261.
31. Post RM, Uhde TW, Ballenger JC (1984) Efficacy of carbamazepine in affective disorders: implications for underlying physiological and biochemical substrates. In: Anticonvulsants in Affective Disorders (Emrich HM, Okuma T, Muller AA, eds.), Amsterdam: Elsevier Science Publishers, pp. 93-115.
32. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OAC, et al. (1999) Reduced cortical γ-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56:1043-1047.
33. Shiah IS, Yatham LN (1998) GABA function in mood disorders: an update and critical review. Life Sci 63:1289-1303.
34. 1A receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 17:382-390.
35. Shiah IS, Yatham LN, Lam RW, Zis AP (1998) Divalproex sodium attenuates growth hormone response to baclofen in healthy human males. Neuropsychopharmacology 18:370-376.
36. Simler S, Randrianarisoa H, Lehaman A, Mandel P (1968) Effects du di-n-propylacetate sur les crises audiogenes de la souris. J Physiol (Paris) 60:547.
37. Spitzer RL, Williams JBW, Gibbon M, First MB (1992) Structured Clinical Interview for DSM-III-R, nonpatient edn. Washington, DC: American Psychiatric Association.
38. SPSS (1996) SPSS for Windows, version 7.5. Chicago, Ill: SPSS Inc.
39. Taberner PV, Charington CB, Unwin JW (1980) Effects of GAD and GABA-T inhibitors on GABA metabolism in vivo. Brain Res Bull 5 (Suppl. 2):621-625.
40. Whittle SR, Turner AJ (1978) Effects of the anticonvulsant sodium valproate on γ-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem 31: 1453-1459.
41. Zimmer R, Teelken AW, Gundurewa M, Ruther E, Cramer H (1980) Effect of sodium-valproate on CSF GABA, cAMP, cGMP, homovanillic acid levels in men. Brain Res Bull 5 (Suppl. 2):585-588.